Arcutis Biotherapeutics Inc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

ARQT$27.39+4.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

	Year Ended December 31,
	2024	2023	2022
Revenues:
Product revenue, net	$166,542	$29,186	$3,686
Other revenue	30,000	30,420	—
Total revenues	196,542	59,606	3,686
Operating expenses:
Cost of sales	19,128	4,987	754
Research and development	76,420	110,575	182,435
Selling, general and administrative	229,391	185,145	122,124
Total operating expenses	324,939	300,707	305,313
Loss from operations	(128,397)	(241,101)	(301,627)
Other income (expense):
Other income, net	16,173	11,786	5,821
Interest expense	(27,168)	(29,712)	(15,652)
Loss before income taxes	(139,392)	(259,027)	(311,458)
Provision for income taxes	647	3,113	—
Net loss	$(140,039)	$(262,140)	$(311,458)
Other comprehensive income (loss):
Unrealized income (loss) on marketable securities	219	1,186	(831)
Foreign currency translation adjustment	(230)	(96)	—
Total other comprehensive income (loss)	(11)	1,090	(831)
Comprehensive loss	$(140,050)	$(261,050)	$(312,289)
Per share information:
Net loss per share, basic and diluted	$(1.16)	$(3.78)	$(5.66)
Weighted-average shares used in computing net loss per share, basic and diluted	120,957,633	69,305,487	55,032,265

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.